Kitov Pharmaceuticals is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval.
Kitov's flagship combination drug, Consensi™, aims to treat osteoarthritis pain and hypertension simultaneously. Consensi™ achieved the primary efficacy endpoint for its Phase III clinical trial, and Kitov submitted a New Drug Application (NDA) in July 2017. The U.S. Food & Drug Administration (FDA) filed the NDA in September 2017, thereby accepting it for a full review. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of May 31, 2018, to complete its review.
Kitov's newest drug, NT-219, which is developed by its majority-owned subsidiary, TyrNovo, is a first-in-class small molecule targeting IRS1/2 and STAT – two signal proteins that are part of an anti-cancer drug resistance mechanism. In various preclinical models where NT-219 was administered in combination with various oncology therapies, outstanding efﬁcacy in preventing acquired resistance and reversing tumor resistance was demonstrated.
By lowering development risk and cost through fast-track regulatory approval of novel therapeutics, Kitov plans to deliver a rapid ROI and long-term potential to investors, while making a meaningful impact on people's lives.
Combination drug meets primary efficacy
endpoint in Phase III trial
Kitov’s Consensi™ is a combination drug that is indicated for the treatment of osteoarthritis pain and hypertension simultaneously. In December 2015, it was announced that the Phase III clinical trial for Consensi™ successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA). Kitov submitted a New Drug Application (NDA) in July 2017. The FDA filed the NDA in September 2017, thereby accepting it for a full review, and under the Prescription Drug User Fee Act (PDUFA), has set a target date of May 31, 2018, to complete its review.
First-in-class small molecule designed
to overcome cancer drug resistance